DOI: https://doi.org/10.22141/2224-1485.1.27.2013.86628

Which ACE inhibitor should be used for secondary stroke prevention?

A.V. Savustyanenko

Abstract


During last decades it was developed more than 10 ACE inhibitors and was largely extended the spectrum of its clinical use. As result it is interesting to answer the question which drug is more suitable for treatment of each certain disease. Ramipril is one of the first choice drugs between ACE inhibitors which possible use for secondary stroke prevention. Current data suggest that this clinical effect is only partially associated with antihypertensive activity of drug. Additional factors include its ability to decrease the progress of atherosclerosis, anti-inflammatory effects (probably), positive effects on glucose metabolism, antiaggregant and anticoagulant properties and the absence of negative effects onto the brain blood flow. Use of ramipril for secondary stroke prevention decreases direct health care costs. Anti-stroke effects of ramipril can be enforced by combined treatment with thiazide diuretic (e.g. indapamide).


Keywords


stroke; secondary prevention; ACE inhibitors; ramipril

References


Using ACE Inhibitors to treat High Blood Pressure and Heart Diseaset Disease: Comparing Effectiveness, Safety, and Price, 2011. — http://consumerhealthchoices.org.

ACE inhibitors and ARBs: Prescribing advice, 2008. — www.warringtonandhaltonhospitals.nhs.uk.

Becker R.A., Schölkens B. Ramipril: review of pharmacology // Am. J. Cardiol. — 1987. — V. 59, № 10. — P. 3D-11D.

Meisel S., Shamiss A., Rosenthal T. Clinical pharmacokinetics of ramipril // Clin. Pharmacokinet. — 1994. — V. 26, № 1. — P. 7-15.

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators / Yusuf S., Sleight P., Pogue J. et al. // N. Engl. J. Med. — 2000. — V. 342, № 3. — P. 145-153.

The HOPE (Heart Outcomes Prevention Evaluation) Study // FDA briefing document. — 2000. — www.fda.gov.

Use of ramipril in preventing stroke: double blind randomised trial / Bosch J., Yusuf S., Pogue J. et al. // BMJ. — 2002. — V. 324, № 7339. — P. 699-702.

Hankey G.J. Angiotensin-converting enzyme inhibitors for stroke prevention: is there HOPE for PROGRESS After LIFE? // Stroke. — 2003. — V. 34, № 2. — P. 354-356.

Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy / Svensson P., de Faire U., Sleight P. et al. // Hypertension. — 2001. — V. 38, № 6. — E28-E32.

Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies / Lonn E., Gerstein H.C., Smieja M. et al. // European Heart Journal Supplements. — 2003. — V. 5 (Supplement A). — P. A43-A48.

Effect of ramipril on the incidence of diabetes / Bosch J., Yusuf S., Gerstein H.C. et al. // N. Engl. J. Med. — 2006. — V. 355, № 15. — P. 1551-1562.

McFarlane S.I. Diabetes prevention between the HOPE and DREAM // Therapy. — 2007. — V. 4, № 1. — P. 1-4.

Differential antiplatelet effects of angiotensin converting enzyme inhibitors: comparison of ex vivo platelet aggregation in cardiovascular patients with ramipril, captopril and enalapril / Skowasch D., Viktor A., Schneider-Schmitt M. et al. // Clin. Res. Cardiol. — 2006. — V. 95, № 4. — P. 212-216.

Long-term angiotensin-converting enzyme inhibition with ramipril reduces thrombin generation in human hypertension / Ekholm M., Wallén N.H., Johnsson H. et al. // Clin. Sci. (Lond). — 2002. — V. 103, № 2. — P. 151-155.

Effects of ramipril and enalapril on cerebral blood flow in elderly patients with asymptomatic carotid artery occlusive disease / Patel R.V., Ramadan N.M., Levine S.R. et al. // J. Cardiovasc. Pharmacol. — 1996. — V. 28, № 1. — P. 48-52.

Carroll C.A., Coen M.M., Rymer M.M. Assessment of the effect of ramipril therapy on direct health care costs for first and recurrent strokes in high-risk cardiovascular patients using data from the Heart Outcomes Prevention Evaluation (HOPE) study // Clin. Ther. — 2003. — V. 25, № 4. — P. 1248-1261.




Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта